This review highlights the multifaceted pathogenesis of cardiovascular disease in obesity and metabolic syndrome, emphasizing the role of insulin resistance, adipokines, and the need for comprehensive lifestyle and pharmacological management.
Answers are grounded in this paper and cite their sources.
Supports targeted pharmacotherapy for metabolic syndrome components except obesity; leaves open optimal long-term obesity strategies.
The metabolic syndrome (MetS) constitutes a multifaceted disorder, including obesity, dyslipidemia, hyperglycemia and hypertension, associated with an increased propensity towards cardiovascular disease (CVD). Besides this, accumulating data suggest the involvement of nontraditional, novel, cardiovascular risk factors in MetS. Among them, insulin resistance seems to possess a predominant role in MetS-related CVD in obese patients. Furthermore, adipose tissue fatty acid metabolism, increased incidence of oxidative stress and endothelial dysfunction, and excessive production of adipocyte derivatives, known as adipokines, have all been proposed to contribute to the pathogenesis of CVD in obese patients with MetS. Lifestyle interventions, such as weight loss and increased physical activity, have long been the cornerstone for the treatment of obesity-related disorders. With the exception of obesity, pharmaceutical interventions targeting each disorder of MetS have yielded considerable improvement in cardiovascular morbidity and mortality. The long-term management of obesity and its complications seems promising but requires further investigation.
No takes yet. Share an insight, caveat, or question.
Nikolopoulou et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: